Status:
COMPLETED
Zithromax EV in Community-Acquired Pneumonia (CAP)
Lead Sponsor:
Pfizer
Conditions:
Pneumonia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The intravenous (IV) regimen containing azithromycin (Zithromax) plus ampicillin-sulbactam is consistent with current guidelines for the treatment of CAP. In fact the International guidelines for the ...
Eligibility Criteria
Inclusion
- Subjects must require hospitalization and intravenous therapy.
- Subjects must have a Fine pneumonia score \> 70 (Fine Class \> II).
- Subjects must have a medical history and clinical and radiological findings consistent with a community-acquired bronchopneumonia or lobar pneumonia. The following criteria must be met:
- new infiltrate(s) on chest X-ray; AND
- at least two of the CAP signs or symptoms.
Exclusion
- Treatment with any systemic antibiotic for 24 hours or longer within 72 hours of the baseline visit, or treatment for more than 7 days within 15 days.
- Specific systemic diseases or other medical conditions that would interfere with the evaluation of the therapeutic response or safety of the study drug, including:
- Known acquired immunodeficiency syndrome (AIDS) or suspected Pneumocystis carinii pneumonia;
- Neutropenia;
- Cavitary lung disease by chest X-ray;
- Primary lung cancer or other malignancy metastatic to the lung;
- Aspiration pneumonia;
- Empyema;
- Known or suspected tuberculosis;
- Neoplastic disease;
- Cystic fibrosis;
- A history of any form of epilepsy or seizure;
- DDM;
- Bronchiectasis, bronchial obstruction or history of post-obstructive pneumonia (this does not exclude patients with chronic obstructive pulmonary disease);
- Significant gastrointestinal or other conditions which may affect study drug absorption; and
- Significant cardiovascular disorders.
- Immunosuppressive therapy, defined as chronic treatment with known immunosuppressant medications
- Impaired hepatic function, as shown by, but not limited to, AST, (SGOT), or ALT (SGPT) greater than three times the laboratory upper limit of normal, or total bilirubin greater than two times the upper limit of normal.
- Subjects already hospitalized or who resided in a long-term-care facility for greater than 14 days before the onset of symptoms.
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2005
Estimated Enrollment :
151 Patients enrolled
Trial Details
Trial ID
NCT00137007
Start Date
November 1 2003
End Date
September 1 2005
Last Update
April 22 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.